The epidemiology of candidemia has changed over the past 20 years, with significant improvements in patient survival and a shift toward community-onset infections and non-albicans species.

1998-2000 Candida spp. (Legacy)  
- C. albicans 50%  
- C. glabrata 19%  
- C. prapsilosis 13%  
- C. tropicalis 12%  
- Other 6%

2019-2020 Candida spp. (New)  
- C. albicans 41%  
- C. glabrata 30%  
- C. prapsilosis 15%  
- C. tropicalis 5%  
- Other 9%

**Patient Outcomes**
- Died: New 35.3%, Legacy 30.8%  
- Survived: New 63.9%, Legacy 67.6%

**Setting of Positive Blood Culture**
- Inpatient: New 75.6%, Legacy 83.2%  
- Outpatient: New 24.4%, Legacy 6.8%